



2009

LOCCANDIA



Lab-on-chip for cancer diagnosis

Pierre GRANGEAT, IEEE Senior Member

**CEA-LETI, MINATEC,
Département microTechnologies pour la Biologie et la Santé
CEA/GRENOBLE, 17, rue des Martyrs,
38054 GRENOBLE cedex 9, France**

E-mail: pierre.grangeat@cea.fr

Tél: +33 4 387843 73

DTBS/STD/09-135



Florence RICOUL(1), Nicolas SARRUT(1), Laurent GERFAULT(1), Caroline PAULUS(1), Grégory STRUBEL(1), Myriam CUBIZOLLES (1), Emeline MERY (1), Lucie BAUJARD LAMOTTE (1), Olivier CONSTANTIN (1), Jean-François GIOVANNELLI(2), Virginie BRUN(3), Alain DUPUIS(3), Jérôme GARIN(3), Jürgen SCHNEKENBURGER(4), Manolis TSIKNAKIS(5), Dimitris KAFETZOPOULOS(5), Manuel PEREZ(6), Blanca JORDAN(6) and the LOCCANDIA and CAPSI project teams.

- (1) CEA-LETI, MINATEC, Département microTechnologies pour la Biologie et la Santé CEA/GRENOBLE, 17, rue des Martyrs, 38054 Grenoble cedex 9, France
- (2) Université de Bordeaux, IMS/LAPS, Equipe Signal et Image, 351 Cours de la Libération, F-33405, Talence cedex, France.
- (3) CEA, DSV, iRTSV / INSERM U880 Etude de la Dynamique des Protéomes, CEA/GRENOBLE, 17, rue des Martyrs, 38054 Grenoble cedex 9, France
- (4) Westfaelische Wilhelms-Universitaet Muenster, Department of Medecine B Gastrointestinal Molecular Cell Biology, Domagkstrasse 3A, Münster, D-48149, Germany
- (5) FORTH, Foundation for Research and Technology – IMBB & ICS, Vassilika Vouton, Heraklion 71110, Greece
- (6) ATOS Research and Innovation, Biotechnology and Health Unit,C/ Albarracin 25, Madrid 28035, Spain

LOCCANDIA Project



FULL TITLE: Lab-On-Chip based protein profiling for CANcer DIAgnosis

Project granted by the European Commission:


Reference: FP6/2005/IST/5/034202

Call: Priority 2.5.2. Micro/nano based sub-system

Web site: <http://www.loccandia.eu>

List of partners:

- Atos Origin sae, Spain – ATOS
- Commissariat à l'Energie Atomique, France – CEA-LETI, CEA-IBITEC
- Foundation for Research and Technology, Greece FORTH
- University of Münster, Germany – WWU
- Swiss Institute of Bioinformatics, Switzerland – SIB
- Geneva Bioinformatics, Switzerland - GeneBIO



Reference: Jordan B. et al. (2008), " LOCCANDIA: Lab-on-Chip Based Protein Profiling for Cancer Diagnosis ", 5th pHealth Workshop on wearable micro and nano systems for personalised health "from research into practice", Valencia, Spain.

Funded by EC contract FP6-034202

LOCCANDIA Project teams LOCCANDIA

- **ATOS:** Blanca Jordán, José F. Esteban, Manuel Perez
- **CEA-LETI:** Pierre Grangeat, Laurent Gerfault, Caroline Paulus, Grégory Strubel, Florence Ricoul, Myriam Cubizolles, Emeline Mery, Lucie Baujard Lamotte, Caroline Fontelaye, Guillaume Nonglaton, Françoise Vinet, Nicolas Sarrut, Olivier Constantin
- **CEA-LEMM:** François FENAILLE, Cédric MESMIN, Eric EZAN
- **FORTH:** Dimitris Kafetzopoulos, Manolis Tsiknakis, Sophie Kaforou, Hara Roumpaki, George Potamias, Haris Kondylakis, Manolis Kalaitz, Vangelis Kritsotakis
- **WWU:** Jürgen Schnekenburger, Verena Schick, Jasna Peter-Katalinic, Laura Bindila, Daniela Hahn, Rainer Ossig
- **SIB:** Frédérique Lisacek
- **GeneBIO:** Pierre-Alain Binz

CAPSI Project

- Full title:
 - chaîne d'analyse protéomique multifactorielle haute sensibilité à composants intégrés
 - high sensitivity multifactorial proteomic analytical chain based on integrated components
- Project granted by the Commissariat à l'Énergie Atomique (CEA) within the program "Technology for healthcare"
- CAPSI project teams:
 - CEA-LETI: Pierre Grangeat, Laurent Gerfault, Caroline Paulus, Grégory Strubel, Florence Ricoul, Myriam Cubizolles, Emeline Mery, Lucie Baujard Lamotte, Agnès Fonverne, Guillaume Nonglaton, Caroline Fontelaye, Françoise Vinet, Nicolas Sarrut, Olivier Constantin
 - CEA-iRTSV-EDyP: Jérôme Garin, Alain Dupuis, Virginie Brun, Dorothee Lebert, Mathieu Trauchessec, Annie Adrait, Christophe Bruley, Véronique Dupierris

The Digital Patient

- The Digital Patient for eHealth :

- The combination of complementary multimodal representations

- The bio-profiles = a multiparametric description

- morphological profiles
 - molecular profiles
 - physiological profiles

- Imaging systems = localisation of the information

- Healthcare objectives = early diagnosis, personnalized healthcare, home healthcare monitoring


The molecular profiles

- a disease is characterized by a **molecular signature** (cancer, infectious disease, immunological disease,...)
- **multiparametric approach** : a set of genes, proteins, therapeutical molecules, functional relationships

➡ Need to recognize **signatures on molecular profiles**

- **molecular profiles** : a fundamental information for personalized healthcare, risk factor analysis, early detection, therapeutical planning and follow-up, drug development, system biology.

The Nano-Bio-Info-Cogno (NBIC) Convergence



The chain for high sensitivity lab-on-chip based proteomic analysis


Lab-on-chip for in-vitro molecular diagnosis

- General trend towards micro-nano bio systems (MNBS) for in vitro diagnosis
- Microfluidics is broadly recognized as a key solution to support molecular diagnostic and point-of-care devices.
- Nanotechnologies for:
 - nanoparticles for in-vitro molecular interaction
 - surface functionalization
 - fluid handling
 - transduction
- Key requirement: to perform better, faster, cheaper and smaller analysis, but still reproducible, sensitive and reliable

Conference highlight

- **Clinical proteomics**
- Micro-nano technologies for microfluidic analysis coupled with mass spectrometry
- Information processing
- Conclusion

Metabolic pathway from DNA to protein



Intracellular genetic information flow from DNA to RNA (transcription) and from RNA to protein (translation)

Source: Alberts, Johnson et al.(2004), Biologie moléculaire de la cellule, Médecines-Sciences, Flammarion

Funded by EC contract FP6-034202





FIGURE 28.33 Schémas d'épissage alternatif. Un pré-mRNA possédant de nombreux exons est parfois épissé de façons différentes. Ici, avec deux exons alternatifs (exons 2A et 2B) présents, le mRNA peut être produit soit avec aucun de ces exons, soit avec l'un ou l'autre, soit avec les deux. Des schémas d'épissage alternatif plus complexes sont aussi possibles.

Splicing between primary RNA and messenger RNA


Ref: Alberts, Johnson et al, Biologie moléculaire de la cellule, Médecines Sciences Flammarion

Funded by EC contract FP6-034202


Alternative splicing produces different isoforms

Ref: Stryer, Berg, Tymoczko, Biochimie, Médecines Sciences Flammarion

Epitope and antibody recognition



An antibody does recognize a specific group of amino-acids at the surface of the protein called epitope




Antibody recognition cannot differentiate between isoforms which include the same epitope

Ref. schéma: Stryer, Berg, Tymoczko,
Biochimie, Médecines Sciences Flammarion

Systems biology

Proteins are key nodes in the biomolecular network studied by systems biology




Source: Aebersold R & Mann M. (2003), Nature, 422, p. 198-207

The 2 main diagnostic modes in proteomic

1. First mode: The cell = a protein sensor

- The protein get attach to the membrane
- The protein get inside the cell
- Diagnostic principle: a marker (a label) is attached to the protein and we image the cells which have captured the labelled proteins. The technique is defined by the type of marker which is used:
 - Nuclear imaging (radioactive marker)
 - Luminescent or fluorescent imaging (luminescent or fluorescent marker)
 - Nuclear Magnetic Resonance imaging (magnetic marker)



The 2 main diagnostic modes in proteomic



2. Second mode: The cell = a protein emitter

Diagnostic principle based on:

- the proteins
- The modification of protein structure
 - Translational modifications
 - Post-translational modifications


The information can be:

- direct: the target is the emitted protein
- indirect: the protein is cleaving a circulating protein that is the target



- **Proteomic:** to describe the molecular signals and the activation states in the cell and its nearby environment
- **Signal network perturbation** induces the fact that the cells do not control anymore their growth, leading to the development of tumoral lesions (unbalanced between survival proteins and apoptosis)
- Each cancer patient has his own pathologic molecular profile.
- **Multiparametric approach:** to combine several markers in order to improve the sensitivity and the specificity.
- Cancer mechanisms linked to proteins:
 - Tumor cells produce aberrant proteins
 - Tumor cells produce cleavage products which degrades proteins within the blood
 - Non-tumor cells respond to signals emitted remotely by tumoral cells


Care cycle of a disease like cancer LOCCANDIA



The challenges of protein analysis in plasma

- High sensitivity
 - Our objective: 1 to 1000 ng/ml
- Very large dynamic ratio in protein concentration:
 - Total protein content in plasma: ~100 mg/ml
 - 1 ng/ml corresponds to a ratio of 1 to 10^8 between the targeted proteins and the total protein content
- A large protein content:
 - About 3000 proteins identified in the plasma by the HPPP

Dynamic range of protein concentration in plasma



Reference intervals for 70 protein analytes in plasma.


Abundance is plotted on a log scale spanning 12 orders of magnitude.

Source: Anderson N.L., Anderson N.G. (2003), Molecular & Cellular Proteomics, Vol 2.1, p. 50.

Funded by EC contract FP6-034202

- The immunological approaches
 - ELISA technique
 - Protein array
- The mass spectrometry approaches (MS)
 - Laser ionisation: SELDI, MALDI
 - Electrospray ionisation: ESI
- Our approach:
 - Combining:
 - immunological recognition
 - chromatography separation
 - electrospray ionisation
 - mass spectrometry separation and quantification

The immuno-chromato-ESI-MS analytical chain



Funded by EC contract FP6-034202


Conference highlight

- Clinical proteomics
- **Micro-nano technologies for microfluidic analysis coupled with mass spectrometry**
- Information processing
- Conclusion



• Point of care :


Full system from blood plasma sample to diagnostic information




• Lab-on-Chip :

Miniaturized integrated components to increase sensitivity (nano-LC, nano-ESI) and throughput

LOCCANDIA Project Goals: Lab-on-chip and mass spectrometry




- The objectives are:
 - to provide new batches of our current microsystems
 - to improve the chromatography-electrospray microsystem technology




- Two interconnected modules will be designed:
 - a protein digestion module
 - a liquid chromatography-electrospray ionisation module

Funded by EC contract FP6-034202


Digestion microreactor




24 devices on a 200 mm silicon wafer



View of the input of the microreactor




SEM view of the hexagonal micropillars



Infrared microscope view of the microreactor


Cyt C at 10pmol/ μ l digested at 10 μ l/min, pellet dissolved at 20pmol/ μ l in 95% H₂O, 5% ACN, 0.05% TFA – Theory: 13 peptides > 3aa




16 peaks corresponding to cyt C:
 - 10 (63%) with 0 misscleavage
 - 4 (25%) with 1 misscleavage
 - 2 (13%) with 2 misscleavages

Chromatography column

Description of the chromatography column



Chromatography column



Physical effects



Microfluidic



Presence of 2 phases
(mobile and stationary
phase)




Convection-diffusion



Saturation effect




adsorption




Peptide competition



Evolution of solvent
composition



Electrospray in front of the mass spectrometer



Electrospray principle

Physical effects



Electro-hydro dynamic



Electro-chemistry



Peptide competition


Evolution of solvent composition

Funded by EC contract FP6-034202

- In chromatography, the detection limit is proportional to the concentration of targeted molecules in elution peak
- The lower is the volume of the elution peak, the higher is the total amount detection limit in the elution peak for a concentration threshold fixed by the mass spectrometer
- Nano-chromatography refers to columns operating on nanoliter volumes
- Nano-chromatography columns allow to detect molecular quantity in the femtomolar range
- 1 femtomole of molecules (~ 10 pg for a molecule of 10 Kdalton) diluted in 1 mL of plasma correspond to a concentration of 1 picomole/L



Why silicon technology ?

- Reproducible technology with high surface/volume ratio



**Micro-pillar structure
for large surface /
volume ratio**

- Optimized hydrodynamic flow *(Computational Fluid Dynamic study from G. Desmet et al, J. Chrom A, 2005)*




Hydrodynamic flow simulation in

a) Capillary with bead packing

b) Perfectly ordered microstructures

Silicon or glass





Deep Reactive Ion Etching

Thick thermal oxidation


Molecular Bonding



Silicon support




Nanoport™ assemblies for capillary connection




Micro-pillar structure for large surface / volume ratio

Funded by EC



Chemical treatment: grafting of trypsin and C₁₈ silane



Grafting of trypsin for the digestion module



Grafting of C₁₈ silane for the chromatographic module




E. Mery, F. Ricoul, N. Sarrut, O. Constantin, G. Delapierre, J. Garin, F. Vinet (2008), A silicon microfluidic chip integrating an ordered micropillars array separation column and a nano-electrospray emitter for LC/MS analysis of peptides, Sensors and Actuators B, Vol. 134, Iss. 2, pp. 438-446.

Conference highlight


- Clinical proteomics
- Micro-nano technologies for microfluidic analysis coupled with mass spectrometry
- **Information processing**
- Conclusion

LOCCANDIA Project Goals : Information technology

**Diagnostic
information**







**Peptides
spectrogram**



To build an Integrated Clinico-Proteomics Environment (ICPE):

- a Proteomic Information Management System (PIS) for sample information management
- a Clinical Information System (CIS) for patient information management to allow clinical evaluation
- an Information and data mediation infrastructure including preprocessing, reconstruction, visualization, protein/peptide identification and data analysis modules



The main stages in image processing



Objectives:

- To manage the acquisition chain parameters
- To quantify the targeted proteins
- To visualize the results
- To identify contaminants
- To manage patient information
- To assist the clinician to take a decision


LOCCANDIA information management system (LIMS)




Identification



Molecular
Profile
Reconstruction



Visualisation




Classification,
Diagnostic assistance

Parameter management:
Patient, Analytical Chain




Funded by EC contract FP6-034202



- Three main approaches are currently investigated:
 - chemometrics approaches associated with factorial analysis
 - statistical approach associated with parametric models
 - dynamic modeling describing the physico-chemical behaviour

State of the art

Methods based on peak detection and peak parameters handling



Area under the curve method

[Radulovic, D. *et al.* (2004) *Mol. Cell. Proteomics* 3, 984-997]

Methods based on full signal handling




Methods based on full signature signal estimation e.g.: PLS

[Idborg, H. *et al.* (2004) *Rapid Commun. Mass Spectrom.* 18, 944-954]


Funded by EC contract FP6-034202

Observed signal

Theoretical signals



Signal mixtures




Shift in chromatographic retention time

© CEA 2008. Tous droits réservés.

Toute reproduction totale ou partielle sur quelque support que ce soit ou utilisation du contenu de ce document est interdite sans l'autorisation écrite préalable du CEA. All rights reserved. Any reproduction in whole or in part on any medium or use of the information contained herein is prohibited without the prior written consent of CEA.

Direct Problem



Inverse problem

Reference:

GRANGEAT P. (2007), "Traitement de l'information", in M. LAHMANI, P. BOISSEAU, P. HOUDY, Les Nanosciences III : Nanobiotechnologies et Nanobiologie, Chapitre 13, 763-789, collection « Echelles » directed by M. LAGUES and A. LESNE, Editions Belin.

GRANGEAT P. (2009), "Data processing", in M. LAHMANI, P. BOISSEAU, P. HOUDY : Nanobiotechnology and Nanobiology, Springer. (to appear).

Funded by EC contract FP6-034202

Acquisition chain model for a peptide

	Modelized phenomena	Model form
Pre-analytic preparation	Dynamic processes	Gain factor
Chromatography	Buffer exchange Convection diffusion equation	Gaussian impulse response
Electrospray	Dynamic process with a small time scale	Gain factor
Mass spectrometry	Sampling+Integration Mathieu equation	Gain factor + Gaussian

The two first moments of the solution

Funded by EC contract FP6-034202

Statistical Reconstruction : direct problem

- Measurement equation :

$$y = F(t).diag(\xi).D.x + F^*(t).diag(\xi).D.x^* + b(\gamma_b)$$

Measure Targeted proteins Labelled targeted proteins Measurement noise

Signatures of targeted and labeled peptides (linked to the peptide retention time) Concentration of targeted proteins System gain Concentration of labeled proteins

White, gaussian and of inverse variance γ_b

- The unknowns:

- the concentrations x
- the instrument parameters (t, ξ)
- the measurement noise parameters γ_b

The a posteriori law:

$$\begin{aligned}
 p(\mathbf{x}, \xi, \mathbf{t}, \gamma_b | \mathbf{Y}) &\propto \exp\left(-\frac{1}{2} \gamma_b \|\mathbf{Y} - \Theta(\mathbf{x}, \mathbf{x}^*, \xi, \mathbf{t})\|^2\right) && \text{Noise: Gaussian law} \\
 &\times \prod_{i=1}^P \exp\left(-\frac{1}{2} \gamma_x^p (x_p - \bar{x}_p)^2\right) && \text{Concentration: Gaussian law} \\
 &\times \prod_{i=1}^I \exp\left(-\frac{1}{2} \gamma_\xi^i (\xi_i - \bar{\xi}_i)^2\right) && \text{System gain: Gaussian law} \\
 &\times \prod_{i=1}^I U(t_i; t_i^m, t_i^M) && \text{Retention time: uniform law} \\
 &\times \frac{\gamma_b^{\alpha_b - 1}}{\beta_b^{\alpha_b} \Gamma(\alpha_b)} \exp\left(-\frac{\gamma_b}{\beta_b}\right) && \text{Noise inverse variance: gamma law}
 \end{aligned}$$

Statistical framework

	Associated law	Notations
Direct model + noise model	Likelihood	$p(Y x, \xi, t, \gamma_b)$
Modeling the <i>a priori</i> information on the parameters	<i>a priori law</i>	$p(x, \xi, t, \gamma_b)$
Combined model	<i>a posteriori law</i>	$p(x, \xi, t, \gamma_b Y)$


Bayes rule:

$$p(x, \xi, t, \gamma_b|Y) = \frac{p(Y|x, \xi, t, \gamma_b)p(x, \xi, t, \gamma_b)}{\int p(Y|x, \xi, t, \gamma_b)p(x, \xi, t, \gamma_b)dx d\xi dt d\gamma_b}$$

Statistical Reconstruction: the inverse problem

- Bayesian reconstruction :
 - Expectation of the A Posteriori law (EAP)

$$[\mathbf{x}, \xi, \mathbf{t}, \gamma_b] = \int [\mathbf{x}, \xi, \mathbf{t}, \gamma_b] p(\mathbf{x}, \xi, \mathbf{t}, \gamma_b | \mathbf{Y}) d\mathbf{x} d\xi d\mathbf{t} d\gamma_b$$



- MCMC (Monte Carlo methods based on Markov Chain) algorithm
 - random sampling of each unknown conditionally to the others
 - computation of the empirical mean of the samples


$$\begin{bmatrix} \hat{x} & \hat{\xi} & \hat{t} & \hat{\gamma}_b \end{bmatrix} \approx \frac{1}{K} \sum_{k=K_0}^{K+K_0-1} \begin{bmatrix} \mathbf{x}^{(k)} & \xi^{(k)} & \mathbf{t}^{(k)} & \gamma_b^{(k)} \end{bmatrix}$$

Reference: STRUBEL G. (2008), "Reconstruction de profils moléculaires: modélisation et inversion d'une chaîne de mesure protéomique (molecular profile reconstruction: modeling and inversion of a proteomic analytical chain)", Ph.D. thesis, INPG, Grenoble, France.


GRANGEAT P., STRUBEL G., GIOVANNELLI J.-F., BRUN V., GERFAULT L., PAULUS C., DUPUIS A., GARIN J. (2009), "Robust statistical reconstruction of protein profiles in mass spectrometry", 57th ASMS Conference on Mass Spectrometry, Philadelphia, Pennsylvania, USA, 31 Mai-4 Juin 2009.

Funded by EC contract FP6-034202


Statistical reconstruction: experimental results



3D display of a zone within the spectrogram around one peptide peak of the targeted protein




2D display of a spectrogram




extracted plot

Comparison between adjusted model (red) and measurement (blue)



Gain variation on the set of experiences




Position variation of chromatographic peak on the set of experiences

Despite these technological variations and the noisy background, the **average variation coefficient is 6.2 %** for the reconstructed protein quantity.


Funded by EC contract FP6-034202

Comparison with standard methods on simulated data




Statistical reconstruction is the most robust against high noise level

Dynamical Reconstruction: the chromatography column model




Dynamical model of the chromatography column

Rereference: PAULUS C., GERFAULT L., BRUN V., GRANGEAT P. (2009), "Inversion of a nano-Liquid Chromatography dynamical model for quantitative proteomics", SYSID 2009: 15th Symposium on System Identification, Saint Malo, France, 6-8 juillet 2009.



Isotherm linking the concentrations in
mobile and stationary phase



Comparison of measured and modelled chromatographic profiles
taking into account the overflow effect

Funded by EC contract FP6-034202

Conference highlight

- Clinical proteomics
- Micro-nano technologies for microfluidic analysis coupled with mass spectrometry
- Information processing
- **Conclusion**

Conclusion

- **OBJECTIVES:**
 - lab-on-chip based point of care dedicated to clinical proteomics from blood sample
 - early detection, treatment planning and follow-up of diseases with proteomic signature such as cancer
 - technological breakthrough will come from the combination of high sensitivity detection and high complexity separation
 - innovative robust molecular profile reconstruction software
- **MULTIDISCIPLINARY RESEARCHES :**
 - Micro-Nano Bio Info Cogno convergence
- **TWO CHALLENGING PROJECTS HAVE BEEN DESCRIBED :**
 - LOCCANDIA & CAPSI
 - First proof of concept are in progress
- **LONG TERM PROJECTS**

Key information processing topics at the sensor level for micro-nano-biomedical-systems

- Inverse problem
 - profile reconstruction
 - source separation
- Statistical signal processing
- Model based signal processing
 - system identification
 - functional model
- Fluid management
- Data analysis:
 - classification
 - decision support
 - signature recognition
 - biostatistics

Advertisement

- **INTERESTED PARTNERS FOR COLLABORATION ARE WELCOME**
- **LOOKING FOR a Ph. D. STUDENT FOR MOLECULAR PROFILE RECONSTRUCTION**

micro and nanoelectronics
microsystems
ambient intelligence
biology and health
image chain



Thank you for your attention

Contact: pierre.grangeat@cea.fr

Web site: <http://www.loccandia.eu>

Team work
Loyalty
Entrepreneurship
Team work
Innovation

**Innovation
for industry**

leti

